Related Experiment Video
Updated: Dec 15, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Glioblastoma and bevacizumab in elderly patients: Monocentric study
Eduardo Barrascout1,2, Michele Lamuraglia3,4
1Medical Oncology Unit, Foch Hospital, Suresnes, France.
Purpose:
A retrospective monocentric comparison of progression-free survival, overall survival, clinical benefit and tolerability between elderly (age>70) and non-elderly (age ≤ 70) patients receiving bevacizumab for recurrent glioblastoma.
Methods:
We analyzed 47 patients with recurrent glioblastoma receiving bevacizumab (10 mg/kg every 14 days) between January 2011 and January 2014. Bevacizumab was introduced for all patients at recurrence after a first-line treatment by temozolomide.
Results:
Nineteen patients were classified as elderly and 28 patients as non-elderly. No statistically significant difference was detected in the groups in terms of progression-free survival (3.8 vs. 4.1 months, p > 0.05) and overall survival at relapse (5.5 vs. 6.5 months, p > 0.05). A significant (p = 0.01) improvement of Karnofsky Performance Status Scale was observed in non-elderly patients.
Conclusions:
Despite the small number of patients in this retrospective study, the efficacy and safety of bevacizumab in recurrent glioblastoma appear similar in elderly and non-elderly patients. However, clinical benefit seemed to be less evident in younger patients. A prospective multicentric study integrating geriatric assessment tools and quality of life metrics would be interesting in this patient population.
Related Concept Videos
Pharmacodynamics in Geriatric Patients: Effects of Age
Treatment Resistant Cancers
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Drug Dosing: Geriatric Patients
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

